Leaders in Pharmaceutical Innovation and Regulatory Excellence

Qualitas Biosciences, LLC is a veterinary consulting firm specializing in the research and development of new veterinary pharmaceuticals and nutritional supplements. We possess expertise in all phases of new product development, launch planning, and regulatory affairs.

Founder and President

Our Founder and President, David L. Bledsoe, DVM, is a licensed veterinarian with three decades of experience in the animal health industry. David has helped develop and launch multiple new animal drugs and supplements. It includes, most recently, Panoquell®-CA1 (fuzapladib sodium for injection)[1], the first and only drug conditionally approved by the FDA for management of clinical signs associated with acute onset of canine pancreatitis.

8,221,792 SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR HIGHLY WATER-SOLUBLE DRUGS
11,752,123 COMPOSITIONS COMPRISING THEANINE, S- ADENOSYLMETHIONINE (SAME), AND/OR MAGNOLIA AND PHELLODENDRON
10,940,130 COMPOSITIONS COMPRISING THEANINE AND WHEY PROTEIN
10,335,384 COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE, AND/OR WHEY PROTEIN

[1] Panoquell® is a Registered Trademark of ISHIHARA SANGYO KAISHA, LTD

Manager of Clinical Trials

Genell C. McCormick, DVM, is a graduate of the St. George’s University College of Veterinary Medicine. She is an experienced small animal practitioner and joined Qualitas Bio in January 2022. Genell is trained in Good Laboratory Practices (GLP) and Good Clinical Practices (GCP) through the Society for Quality Assurance. She uses her clinical practice experience to inform her role as Manager of Clinical Trials at Qualitas Bio.